Intravitreal Injections and Diabetic Macular Edema: Actual and New Therapeutic Options
Nicola Pescosolido, Federica Pranno and Giuseppe Buomprisco
Affiliation: University “Sapienza” of Rome, Faculty of Medicine and Dentistry, Department of Cardiovascular, Respiratory, Nephrologic, Anesthesiologic and Geriatric Sciences, Viale del Policlinico 155, 00161, Rome, Italy.
The management of diabetic macular edema (DME) has been revolutionized in recent years. Focal and focal/
grid laser photocoagulation have been the mainstay of treatment for DME for much time. However, nowadays, there is
growing evidence that intravitreal VEGF-inhibitors (combined or not with laser photocoagulation) provide better visual
outcome in patients with diabetic retinopathy. Hence, anti-VEGF injections are considered the new gold standard to treat
diabetic macular edema and eyes with a reduced visual function. Further studies assessing different treatment regimens
are underway to define better clinical care pathways.
Keywords: Anti-VEGF, diabetic macular edema, diabetes, neovascularization, rethinopathy, vision loss prevention.
Rights & PermissionsPrintExport